. Author manuscript; available in PMC: 2012 Nov 1.

Published in final edited form as: J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):233–240. doi: 10.1097/QAI.0b013e318228667f

Table 1.

Patient information

Patient Characteristic	ARV-Experienced Patients failing Treatment (n=45)	ARV-Naïve Patients (n=45)	p-value
Age, median years (Q1–Q3)	36 (24–51)	36 (20–78)	0.65
Gender: Female	28 (65%)	27 (60%)
Black race	45 (100%)	45 (100%)
CD4 cell count, median cells/mm³ (Q1–Q3)
Current	174 (9–718)	123 (8–660)	0.036
Nadir	57 (3–197)		0.0004
Vial load, median copies/ml	6, 653 (225-220,010)	44,042 (1,702–1,167,759)	0.0010
Current treatment regimen:		Current treatment regimen:
Regimen 1A (d4T, 3TC, EFV)	23 (51.1%)	Regimen 1A (d4T, 3TC, EFV)	23 (51.1%)
Regimen 1B (d4T, 3TC, NVP)	2 (4.4%)	Regimen 1B (d4T, 3TC, NVP)	2 (4.4%)
ZDV, d4T, ddI, NVP	1 (2.2%)	ZDV, d4T, ddI, NVP	1 (2.2%)
ZDV, d4T, 3TC, EFV	2 (4.4%)	ZDV, d4T, 3TC, EFV	2 (4.4%)
ZDV, 3TC, EFV	13 (29.0%)	ZDV, 3TC, EFV	13 (29.0%)
ZDV, 3TC,NVP	4 (8.9%)	ZDV, 3TC,NVP	4 (8.9%)

Of these, 11/27 (40.8%) had previous history of Regimen 1A. 2/27 (7.4%) had a previous history of d4T, 3TC, NVP and EFV; 2/27 (7.4%) had a previous history of d4T and NVP and 1/27 (3.7%) each had previous history of the following: AZT, d4T, 3TC, ddI, EFV; d4T, NVP, EFV; AZT, 3TC, NVP, Lopinivir/Ritonivir; AZT, d4T, EFV; AZT, 3TC, Lopinivir/Ritonivir; AZT, d4T, 3TC, NVP; d4T, 3TC; AZT, d4T, NVP; 3TC, ddI, EFV; AZT, 3TC, EFV; d4T, 3TC, ddI, EFV; and AZT, 3TC,ddI.